NASDAQ:KRTX
Karuna Therapeutics, Inc. Stock News
$329.83
+0 (+0%)
At Close: May 20, 2024
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and
Karuna Therapeutics to Present at Upcoming Investor Conferences
06:30am, Wednesday, 01'st Nov 2023
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and
Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023
06:30am, Thursday, 19'th Oct 2023
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychi
Karuna Therapeutics: KarXT Could Become A New Standard Of Care In Schizophrenia
02:41pm, Monday, 16'th Oct 2023
Karuna Therapeutics, Inc. stock had >8x gain after my Buy rating before successful Phase 3 trial data for KarXT in treating schizophrenia. The stock has pulled back and is at a good buy level ahead of
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and
Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug
02:17pm, Friday, 29'th Sep 2023
If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. Data from three clinical studies support the FDA filing.
Karuna Therapeutics to Present at Upcoming Investor Conferences
06:30am, Wednesday, 30'th Aug 2023
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric a
Karuna: NDA Filing Q3 Of 2023 And Expanded Potential With KarXT
02:54pm, Thursday, 24'th Aug 2023
Submission of New Drug Application of KarXT for the treatment of schizophrenia is expected in Q3, 2023. If FDA approval of KarXT is given for the treatment of patients with schizophrenia then commerci
Karuna's Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade)
05:08pm, Wednesday, 16'th Aug 2023
Karuna Therapeutics develops innovative treatments for psychiatric and neurological disorders, with their investigational drug KarXT targeting schizophrenia and Alzheimer's-related psychosis. Karuna T
Karuna Therapeutics, Inc. (KRTX) Q2 2023 Earnings Call Transcript
05:02am, Saturday, 05'th Aug 2023
Karuna Therapeutics, Inc. (NASDAQ:KRTX ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Alexis Smith - Senior Director of Investor Relations William Meury - President
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q2
02:17pm, Friday, 04'th Aug 2023
Karuna (KRTX) reports mixed second-quarter 2023 results. The company beats estimates for earnings but misses the mark on sales.
Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023
06:30am, Thursday, 20'th Jul 2023
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric a
Andreas Halvorsen Curbs Roivant Sciences Stake
05:53pm, Tuesday, 27'th Jun 2023
Andreas Halvorsen (Trades, Portfolio), the chief investment officer of Viking Global Investors, disclosed earlier this week he reduced his stake in Roivant Sciences Ltd. ( ROIV , Financial) by 14.73%.
Karuna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
06:30am, Tuesday, 30'th May 2023
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric a
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric a